Recruiting Major Depressive Disorder Studies in Atlanta
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD....
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical...
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD....
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants ...
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for us...
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive diso...
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not respond...
PD, PK, and Safety of ALTO-203 in Patients With MDD
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, ...
About Major Depressive Disorder Clinical Trials in Atlanta
Major depressive disorder (MDD) is a severe form of depression characterized by persistent sadness, loss of interest, and impaired daily functioning. Treatment-resistant depression (TRD) affects patients who do not respond to standard therapies. Novel treatments like ketamine, psilocybin, and neuromodulation are being studied.
There are currently 8 major depressive disorder clinical trials recruiting participants in Atlanta, GEORGIA. These studies are seeking a combined 2,888 participants. Research is being sponsored by Neurocrine Biosciences, Intra-Cellular Therapies, Inc., Cybin IRL Limited and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Major Depressive Disorder Clinical Trials in Atlanta — FAQ
Are there major depressive disorder clinical trials in Atlanta?
Yes, there are 8 major depressive disorder clinical trials currently recruiting in Atlanta, GEORGIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Atlanta?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.
Are clinical trials in Atlanta free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.
What major depressive disorder treatments are being tested?
The 8 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for major depressive disorder.
Data updated March 2, 2026 from ClinicalTrials.gov